Developer docs
API playgroundTry for free, no card

Search company profiles

StemSight

Full company profile

uuid00027gs

Namestring
StemSight
Legal namestring
StemSight
Websiteurl
stemsight.fi
Company typeenum
Private
Founded yearint
2021
Descriptiontext

StemSight is a Tampere, Finland-based biotechnology company founded in 2021 that develops off-the-shelf cell therapies for corneal blindness, with a primary focus on Limbal Stem Cell Deficiency (LSCD). Its lead candidate STE-101 is an iPS cell-derived limbal stem cell therapy that replaces lost limbal stem cells to restore vision, and the product is positioned to benefit from Advanced Therapy Medicinal Product (ATMP) and Orphan Drug Designation frameworks. The platform combines induced pluripotent stem cell technology — developed by Nobel laureate Shinya Yamanaka and matured over 15+ years at Tampere University's Skottman Lab — with functional biomaterials (hyaluronic acid hydrogels) designed to simplify cell delivery and accelerate tissue regeneration. Differentiation methods produce corneal epithelial cells with validated ABCB5+ and ΔNp63α+ markers, and StemSight has additionally licensed CRISPR/Cas9 IP from ERS Genomics to enable selective gene knock-out in iPS cells. The company also participates in the €8M EU-funded KeratOPrinter consortium developing 3D bioprinted full-thickness corneas.

StemSight operates as a pre-clinical, venture-backed private company headquartered at Finn-Medi 5 in Tampere with a team of approximately 15 scientists and executives. Its go-to-market is built on enterprise/B2B biotech motions: future revenue is expected to flow through direct sales of cell therapy products to ophthalmology hospitals, specialty eye clinics, and healthcare systems, supplemented by licensing, co-development, and manufacturing partnerships with larger pharmaceutical and automation partners (e.g., Mytos for automated production). To date the company has financed operations through an approximately €500K pre-seed round (Voima Ventures, 2021), a €2.3M seed round (Voima Ventures-led with Business Finland non-dilutive funding, Stephen Industries, Biothom, 2025), and roughly €1.9M in cumulative non-dilutive grants (Business Finland Deep Tech Accelerator, Instrumentarium Science Foundation Silmu grant, WomenTechEU, and EU regional development funding).

The addressable indication is large — corneal blindness affects more than 12 million people globally and the company explicitly cites the donor-tissue shortage and the absence of treatment options for bilateral LSCD as the unmet need it is pursuing. Pricing of the eventual ATMP has not been disclosed and will be set upon regulatory approval through reimbursement negotiations with healthcare systems. The company has signaled a Series A financing round to fund clinical development and commercial preparation, with parallel platform expansion into corneal endothelial dystrophies and active outreach across European biotech investor events.

Short descriptiontext

StemSight is a Tampere, Finland-based biotech founded in 2021 that develops off-the-shelf iPS cell-derived cell therapies for corneal blindness, with lead candidate STE-101 targeting Limbal Stem Cell Deficiency and future expansion into corneal endothelial dystrophies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersTampere, Finland
HQ citystring
Tampere
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy products, regenerative medicine, corneal blindness treatment, limbal stem cell therapy, iPSC cell therapy
Industry3 codes
PRIMARYHLAAAGAK
Ophthalmic Regeneration (cornea/retina)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
Product category
Cell Therapy / Regenerative Ophthalmology
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Cell Therapy Product Sales
TypeOne Time License
Description

StemSight develops and commercializes off-the-shelf cell therapy products (starting with STE-101 for LSCD) through direct sales to healthcare providers and hospital systems. Revenue will come from product sales to treating corneal blindness patients globally.

stemsight.fi
2Licensing and Partnerships
TypeLicensing Royalties
Description

Future potential revenue through licensing of technology platform, co-development partnerships, and manufacturing partnerships with larger pharmaceutical companies for global distribution.

stemsight.fi
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

StemSight develops off-the-shelf iPS cell-derived cell therapies combined with functional biomaterials to treat corneal blindness. Their lead product candidate STE-101 is an iPS-derived limbal stem cell therapy that replaces lost limbal stem cells to restore vision in patients with Limbal Stem Cell Deficiency (LSCD), without requiring genetic engineering or donor tissue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Off-the-shelf cell therapy eliminating donor tissue dependency
+1 more record
Product overview1 text field

StemSight is a biotech company developing off-the-shelf cell therapies for corneal blindness. The company's core product is STE-101, an iPS cell-derived therapy for limbal stem cell deficiency (LSCD). StemSight combines induced pluripotent stem (iPS) cells with functional biomaterials to accelerate tissue regeneration and simplify cell delivery. Their technology platform is built on Nobel Prize-winning iPSC technology developed at Shinya Yamanaka's laboratory.

Product and service1 record
1STE-101
CategoryCell Therapy Product
Description

Off-the-shelf iPS cell-derived therapy for the treatment of limbal stem cell deficiency (LSCD), targeting partial or total unilateral or bilateral forms of the condition. The therapy replaces damaged limbal stem cells without requiring genetic engineering and is intended for ophthalmology hospitals and specialty eye clinics treating corneal blindness patients.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-03
Description

Mytos, a London-based biotechnology company automating cell manufacturing, announced a manufacturing collaboration with StemSight to integrate its iDEM automated platform for scaling production of StemSight's lead product STE-101. The collaboration aims to enable production of cell therapies from early clinical trials toward commercial-ready manufacturing, representing a validation of Mytos' technology and the industry shift toward automation in advanced cell therapies.

2KeratOPrinter Project Consortium
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-08
Description

StemSight is part of the €8M EU-funded KeratOPrinter project aimed at revolutionizing corneal transplantation using advanced 3D bioprinting technology to create full-thickness, biocompatible corneas. The collaborative effort involves partners from five EU countries to address the global shortage of donor tissue and restore vision for millions.

stemsight.fi
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-01-17
Description

StemSight entered a licensing agreement with ERS Genomics for CRISPR/Cas9 foundational intellectual property. This Nobel-winning 'genetic scissors' technology allows selective knock-out of target genes in iPS cells, enabling trait modification that passes to resulting therapeutic cells.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-08-31
Description

Finnish Research Impact Foundation awarded StemSight and Tampere University's joint Tandem Industry Academia 2-year project. The technology originated from Professor Heli Skottman's Lab at Tampere University where academic research continues to develop new regenerative solutions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

US clinical-stage cell therapy company developing autologous cell therapies for kidney disease. Comparable as a clinical-stage, regenerative-medicine cell therapy developer, though focused on renal rather than ophthalmic indications.

2Sigilon Therapeutics
TypeEmerging player
Description

US clinical-stage biotech developing encapsulated cell therapies for chronic diseases. Comparable as an emerging allogeneic cell therapy company tackling complex delivery challenges, though its lead indications are non-ophthalmic.

TypeBroad incumbent
Description

Australian-listed late-stage cell therapy company commercializing allogeneic mesenchymal stem cell products (Remestemcel-L). Comparable as an established allogeneic cell therapy developer with regulatory experience in advanced therapies.

TypeRegional player
Description

Subsidiary of Teijin, J-TEC is the leading Japanese regenerative medicine company commercializing autologous corneal epithelial cell therapies (e.g., for LSCD) and other cell-based products. Comparable as a regional ophthalmic cell therapy player serving the Japanese market.

TypeBroad incumbent
Description

US clinical-stage cell therapy company with programs in retinal/eye indications (e.g., OpRegen for dry AMD using RPE cells) and broader regenerative medicine. Overlaps as a cell therapy developer in ophthalmology, particularly for retinal diseases.

TypeBroad incumbent
Description

US clinical-stage biotech developing iPSC-derived NK and T-cell immunotherapies using a proprietary iPSC platform. Comparable as a leading iPSC-derived allogeneic cell therapy company, though focused on oncology rather than ophthalmology.

TypeDirect peer
Description

Italian biotech that developed Holoclar, the first approved advanced therapy for LSCD (using autologous limbal stem cells). Holostem is the most direct competitor — both target LSCD with stem cell therapies, though Holostem uses autologous rather than allogeneic iPSC-derived cells.

8Pluristem Therapeutics
TypeBroad incumbent
Description

Israeli clinical-stage cell therapy company using placenta-derived mesenchymal-like adherent stromal cells (PLX cells). Comparable as an allogeneic, off-the-shelf cell therapy platform company, though targeting different indications.

9Cynata Therapeutics
TypeDirect peer
Description

Australia-listed clinical-stage biotech developing iPSC-derived cell therapies (Cymerus platform). Direct peer in iPSC-derived allogeneic cell therapy, and shares leadership lineage with StemSight (former Cynata CEO Ross Macdonald is now StemSight's CCO).

TypeOthers
Description

Major CDMO with significant cell therapy manufacturing capabilities, often partnering with or supplying developers of allogeneic cell therapies including those in ophthalmology. Comparable as an enabling infrastructure partner in the cell therapy supply chain.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

StemSight

Cell Therapy / Regenerative Ophthalmologystemsight.fi

StemSight is a Tampere, Finland-based biotech founded in 2021 that develops off-the-shelf iPS cell-derived cell therapies for corneal blindness, with lead candidate STE-101 targeting Limbal Stem Cell Deficiency and future expansion into corneal endothelial dystrophies.

What StemSight does

StemSight is a Tampere, Finland-based biotechnology company founded in 2021 that develops off-the-shelf cell therapies for corneal blindness, with a primary focus on Limbal Stem Cell Deficiency (LSCD). Its lead candidate STE-101 is an iPS cell-derived limbal stem cell therapy that replaces lost limbal stem cells to restore vision, and the product is positioned to benefit from Advanced Therapy Medicinal Product (ATMP) and Orphan Drug Designation frameworks. The platform combines induced pluripotent stem cell technology — developed by Nobel laureate Shinya Yamanaka and matured over 15+ years at Tampere University's Skottman Lab — with functional biomaterials (hyaluronic acid hydrogels) designed to simplify cell delivery and accelerate tissue regeneration. Differentiation methods produce corneal epithelial cells with validated ABCB5+ and ΔNp63α+ markers, and StemSight has additionally licensed CRISPR/Cas9 IP from ERS Genomics to enable selective gene knock-out in iPS cells. The company also participates in the €8M EU-funded KeratOPrinter consortium developing 3D bioprinted full-thickness corneas.

StemSight operates as a pre-clinical, venture-backed private company headquartered at Finn-Medi 5 in Tampere with a team of approximately 15 scientists and executives. Its go-to-market is built on enterprise/B2B biotech motions: future revenue is expected to flow through direct sales of cell therapy products to ophthalmology hospitals, specialty eye clinics, and healthcare systems, supplemented by licensing, co-development, and manufacturing partnerships with larger pharmaceutical and automation partners (e.g., Mytos for automated production). To date the company has financed operations through an approximately €500K pre-seed round (Voima Ventures, 2021), a €2.3M seed round (Voima Ventures-led with Business Finland non-dilutive funding, Stephen Industries, Biothom, 2025), and roughly €1.9M in cumulative non-dilutive grants (Business Finland Deep Tech Accelerator, Instrumentarium Science Foundation Silmu grant, WomenTechEU, and EU regional development funding).

The addressable indication is large — corneal blindness affects more than 12 million people globally and the company explicitly cites the donor-tissue shortage and the absence of treatment options for bilateral LSCD as the unmet need it is pursuing. Pricing of the eventual ATMP has not been disclosed and will be set upon regulatory approval through reimbursement negotiations with healthcare systems. The company has signaled a Series A financing round to fund clinical development and commercial preparation, with parallel platform expansion into corneal endothelial dystrophies and active outreach across European biotech investor events.

StemSight firmographics

Firmographics
Name
StemSight
Legal name
StemSight
Website
https://stemsight.fi
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
StemSight is a Tampere, Finland-based biotech founded in 2021 that develops off-the-shelf iPS cell-derived cell therapies for corneal blindness, with lead candidate STE-101 targeting Limbal Stem Cell Deficiency and future expansion into corneal endothelial dystrophies.
Ownership category
akta.pro rank

StemSight industry classification

Industry
Product category
Cell Therapy / Regenerative Ophthalmology
akta.pro industry
PRIMARYHLAAAGAK
Ophthalmic Regeneration (cornea/retina)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAE
Stem Cell Therapies (MSC/iPSC/HSC-derived)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy products
  • Regenerative medicine
  • Corneal blindness treatment
  • Limbal stem cell therapy
  • IPSC cell therapy

Where StemSight is headquartered

Location

Headquarters

HQ city
Tampere
HQ country
Finland
HQ region
Europe

Offices1 record

Markets served

StemSight business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Cell Therapy Product Sales: StemSight develops and commercializes off-the-shelf cell therapy products (starting with STE-101 for LSCD) through direct sales to healthcare providers and hospital systems. Revenue will come from product sales to treating corneal blindness patients globally.
  2. Licensing and Partnerships: Future potential revenue through licensing of technology platform, co-development partnerships, and manufacturing partnerships with larger pharmaceutical companies for global distribution.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

StemSight product offering

Product offering

Core offering

StemSight develops off-the-shelf iPS cell-derived cell therapies combined with functional biomaterials to treat corneal blindness. Their lead product candidate STE-101 is an iPS-derived limbal stem cell therapy that replaces lost limbal stem cells to restore vision in patients with Limbal Stem Cell Deficiency (LSCD), without requiring genetic engineering or donor tissue.

Product overview

StemSight is a biotech company developing off-the-shelf cell therapies for corneal blindness. The company's core product is STE-101, an iPS cell-derived therapy for limbal stem cell deficiency (LSCD). StemSight combines induced pluripotent stem (iPS) cells with functional biomaterials to accelerate tissue regeneration and simplify cell delivery. Their technology platform is built on Nobel Prize-winning iPSC technology developed at Shinya Yamanaka's laboratory.

Differentiator

Problem solved

Functional benefit

Products and services

  • STE-101 Off-the-shelf iPS cell-derived therapy for the treatment of limbal stem cell deficiency (LSCD), targeting partial or total unilateral or bilateral forms of the condition. The therapy replaces damaged limbal stem cells without requiring genetic engineering and is intended for ophthalmology hospitals and specialty eye clinics treating corneal blindness patients.

Quantifiable outcome

  • Off-the-shelf cell therapy eliminating donor tissue dependency
  • +1 more outcomes

Companies that use StemSight

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

StemSight technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

StemSight partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • MytoscoreTechnology or Integration · 3 September 2025Mytos, a London-based biotechnology company automating cell manufacturing, announced a manufacturing collaboration with StemSight to integrate its iDEM automated platform for scaling production of StemSight's lead product STE-101. The collaboration aims to enable production of cell therapies from early clinical trials toward commercial-ready manufacturing, representing a validation of Mytos' technology and the industry shift toward automation in advanced cell therapies.
  • KeratOPrinter Project ConsortiumcoreStrategic or Co-development Partner · 8 April 2025StemSight is part of the €8M EU-funded KeratOPrinter project aimed at revolutionizing corneal transplantation using advanced 3D bioprinting technology to create full-thickness, biocompatible corneas. The collaborative effort involves partners from five EU countries to address the global shortage of donor tissue and restore vision for millions.
  • ERS GenomicscoreOEM/ Whitelabel/ Licensing Partner · 17 January 2024StemSight entered a licensing agreement with ERS Genomics for CRISPR/Cas9 foundational intellectual property. This Nobel-winning 'genetic scissors' technology allows selective knock-out of target genes in iPS cells, enabling trait modification that passes to resulting therapeutic cells.
  • Tampere UniversitycoreStrategic or Co-development Partner · 31 August 2023Finnish Research Impact Foundation awarded StemSight and Tampere University's joint Tandem Industry Academia 2-year project. The technology originated from Professor Heli Skottman's Lab at Tampere University where academic research continues to develop new regenerative solutions.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

StemSight competitors and assessment

Company assessment

Emerging players

  • ProKidney: US clinical-stage cell therapy company developing autologous cell therapies for kidney disease. Comparable as a clinical-stage, regenerative-medicine cell therapy developer, though focused on renal rather than ophthalmic indications.
  • Sigilon Therapeutics: US clinical-stage biotech developing encapsulated cell therapies for chronic diseases. Comparable as an emerging allogeneic cell therapy company tackling complex delivery challenges, though its lead indications are non-ophthalmic.

Broad incumbents

  • Mesoblast: Australian-listed late-stage cell therapy company commercializing allogeneic mesenchymal stem cell products (Remestemcel-L). Comparable as an established allogeneic cell therapy developer with regulatory experience in advanced therapies.
  • Lineage Cell Therapeutics: US clinical-stage cell therapy company with programs in retinal/eye indications (e.g., OpRegen for dry AMD using RPE cells) and broader regenerative medicine. Overlaps as a cell therapy developer in ophthalmology, particularly for retinal diseases.
  • Fate Therapeutics: US clinical-stage biotech developing iPSC-derived NK and T-cell immunotherapies using a proprietary iPSC platform. Comparable as a leading iPSC-derived allogeneic cell therapy company, though focused on oncology rather than ophthalmology.
  • Pluristem Therapeutics: Israeli clinical-stage cell therapy company using placenta-derived mesenchymal-like adherent stromal cells (PLX cells). Comparable as an allogeneic, off-the-shelf cell therapy platform company, though targeting different indications.

Regional players

  • Japan Tissue Engineering (J-TEC): Subsidiary of Teijin, J-TEC is the leading Japanese regenerative medicine company commercializing autologous corneal epithelial cell therapies (e.g., for LSCD) and other cell-based products. Comparable as a regional ophthalmic cell therapy player serving the Japanese market.

Direct peers

  • Holostem Terapie Avanzate: Italian biotech that developed Holoclar, the first approved advanced therapy for LSCD (using autologous limbal stem cells). Holostem is the most direct competitor — both target LSCD with stem cell therapies, though Holostem uses autologous rather than allogeneic iPSC-derived cells.
  • Cynata Therapeutics: Australia-listed clinical-stage biotech developing iPSC-derived cell therapies (Cymerus platform). Direct peer in iPSC-derived allogeneic cell therapy, and shares leadership lineage with StemSight (former Cynata CEO Ross Macdonald is now StemSight's CCO).

Others

  • Catalent (Cell & Gene Therapy): Major CDMO with significant cell therapy manufacturing capabilities, often partnering with or supplying developers of allogeneic cell therapies including those in ophthalmology. Comparable as an enabling infrastructure partner in the cell therapy supply chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

StemSight social profiles

Digital presence

StemSight compliance and trust

Trust signal

Compliance2 records

StemSight financial estimates

Financial estimate

Revenue estimate

Valuation estimate

StemSight leadership team

Management profile

Number of profiles

Profiles18 records

StemSight funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

StemSight M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about StemSight

What does StemSight do?

StemSight develops off-the-shelf iPS cell-derived cell therapies combined with functional biomaterials to treat corneal blindness. Their lead product candidate STE-101 is an iPS-derived limbal stem cell therapy that replaces lost limbal stem cells to restore vision in patients with Limbal Stem Cell Deficiency (LSCD), without requiring genetic engineering or donor tissue.

Is StemSight a public or private company?

StemSight is a private company. It is classified as venture growth investor backed and is currently operating.

When was StemSight founded?

StemSight was founded in 2021. It employs 11 to 50 people.

Where is StemSight based?

StemSight is headquartered in Tampere, Finland, in the Europe region.

How does StemSight make money?

Two revenue lines are on record. Cell Therapy Product Sales are the primary driver. The others are licensing and Partnerships.

Who are StemSight's main competitors?

Emerging players on record are ProKidney and Sigilon Therapeutics. Broad incumbents are Mesoblast, Lineage Cell Therapeutics, Fate Therapeutics and Pluristem Therapeutics. Japan Tissue Engineering (J-TEC) is listed as a regional player. Direct peers are Holostem Terapie Avanzate and Cynata Therapeutics. Catalent (Cell & Gene Therapy) is listed as an others.

Does StemSight have an API?

No public API is recorded for StemSight.

What industry is StemSight in?

StemSight's product category is Cell Therapy / Regenerative Ophthalmology. Its primary akta.pro industry code is HLAAAGAK, Ophthalmic Regeneration (cornea/retina), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceMytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy TrialsMytos, a London-based biotechnology company automating cell manufacturing, announced new manufacturing collaborations with StemSight, Rinri Therapeutics, and Novadip to integrate its iDEM automated platform across diverse therapeutic applications including ocular diseases, hearing loss, and bone regeneration. The partnerships represent a validation of Mytos' technology, enabling each biotech company to scale production of cell therapies from early clinical trials toward commercial-ready manufacturing. The collaborations reflect a broader industry shift toward automation in advanced cell therapies as the field matures toward patient-scale delivery.Voima VenturesFrom Lab to Launch: A Researcher’s Guide to Spinning Out a Deep Tech StartupVoima Ventures published a guide for deep tech researchers on spinning out startups, featuring insights from CEOs of N-Ink, StemSight, and Cellfion regarding the challenges of commercializing laboratory research. The article emphasizes the necessity of aligning with industry requirements early, securing patient capital through grants like those from Vinnova or the EIC Accelerator, and demonstrating execution capability to investors.AinStartup of the Day: Finnish biotech StemSightStemSight, a Finnish biotech, develops stem cell therapies for corneal blindness, focusing on Limbal Stem Cell Deficiency. The company raised 500,000 EUR in 2021 and 1 million EUR in late 2024, with plans for preclinical trials by end of 2025 and first-in-human trials in 2027.AinStemSight raises €2.3M for stem cell-based vision restoration therapiesStemSight raised €2.3 million from Voima Ventures, Business Finland, and other investors. The funding will support preclinical studies, R&D, and manufacturing pilots for its stem cell therapy targeting severe corneal blindness. The company plans to expand its pipeline to address additional ocular diseases.RunditCompany Fundraising News: October 2024Rundit has published its October 2024 fundraising newsletter, featuring multiple startups seeking capital from its network of over 10,000 venture capitalists and 1,000+ angel investors. The newsletter highlights seven companies across diverse sectors including marketplaces, health tech, biotech, robotics, and AI software, collectively raising rounds ranging from Seed to Series A stages. Key featured companies include Vendora (€5M Series A), Adamant Health (€3M equity + €2M non-dilutive), Mia Health AS (€2M Seed), StemSight (€2M equity), Danu Robotics (£2M Seed), Ocean's Balance ($1.75M Seed), and Wudpecker (€1M Seed).Voima VenturesStemSight cures blindness with stem cellsStemSight, a cell therapy startup based in Finland, has launched and secured a €500k seed round from investors Voima Ventures and Avohoidon Tutkimussäätiö. The company aims to treat corneal blindness by manufacturing new corneal cells from human stem cells, addressing the shortage of donor tissue.PaaomasijoittajatStemSight cures blindness with stem cellsStemSight, a company founded by researchers from Tampere University, has launched and secured a €500k seed round from investors Voima Ventures and Avohoidon Tutkimussäätiö. The firm aims to treat corneal blindness using stem cell technology to manufacture new corneal cells, addressing the shortage of donor tissue.